Amanda Andrade, DO
Family Medicine · Joplin, MONPI 1528354008
Payments from drug & device makers
Across 342 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$572
- AstraZeneca$441
- Lilly USA, LLC$352
- Amgen$286
- Boehringer Ingelheim$253
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,046100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $1,013 |
| Novo Nordisk | 38 | $572 |
| AstraZeneca | 23 | $441 |
| Lilly USA, LLC | 22 | $352 |
| Amgen | 16 | $286 |
| Boehringer Ingelheim | 16 | $253 |
| Pfizer | 19 | $246 |
| Abbott | 12 | $234 |
| GSK | 13 | $199 |
| Merck | 11 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $129 |
| Dexcom, Inc. | 8 | $123 |
| Idorsia Pharmaceuticals US Inc | 6 | $114 |
| Novartis | 7 | $106 |
| Otsuka America Pharmaceutical, Inc. | 6 | $103 |
| Johnson & Johnson | 5 | $76 |
| Astellas Pharma US Inc | 4 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Amarin Pharma, Inc. | 3 | $56 |
| Bayer | 3 | $51 |
| Exact Sciences | 3 | $44 |
| Eisai Inc. | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Globus Medical | 1 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Shield Therapeutics Inc | 1 | $13 |
| Circassia Inc. | 1 | $11 |
| Endogastric Solutions, Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,046 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $148,935 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 94 | $83,609 |
| JardianceEmpagliflozin | 79 | $78,500 |
| FarxigaDapagliflozin Propanediol | 68 | $69,043 |
| RexultiBrexpiprazole | 37 | $67,031 |
| MounjaroTirzepatide | 42 | $62,140 |
| EliquisApixaban | 53 | $61,117 |
| Repatha SureclickEvolocumab | 55 | $52,310 |
| LinzessLinaclotide | 41 | $40,461 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $34,923 |
| TrulicityDulaglutide | 27 | $29,929 |
| ProliaDenosumab | 14 | $23,835 |
| MyrbetriqMirabegron | 35 | $22,615 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $21,145 |
| QuliptaAtogepant | 16 | $20,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga | $441 | $152,652162 claims |
| Novo NordiskOzempic | $572 | $148,93598 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $253 | $113,423126 claims |
| Lilly USA, LLCMounjaro, Trulicity | $352 | $92,07069 claims |
| PfizerEliquis, Lyrica, Premarin, Abrysvo | $246 | $77,89292 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $103 | $67,03137 claims |
| AbbVieLinzess, Qulipta | $1,013 | $60,80957 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $199 | $46,31973 claims |
| AmgenProlia | $286 | $23,83514 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $22,61535 claims |
| Johnson & JohnsonXarelto | $76 | $13,26818 claims |
| MerckBelsomra | $150 | $6,94714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Joplin
- Luke WickeJoplin$18K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.